Inflammation and the use of anti-inflammatory agents in signs and cardiovascular consequences of metabolic syndrome

Handbook on Metabolic Syndrome: Classification, Risk Factors and Health Impact

Volumn , Issue , 2012, Pages 169-188

  Rubio Ruiz, María Esther ^a   Lans, Verónica Guarner ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

Anti infalmmatory agents; Atherosclerosis; Dyslipidemia; Hypertension; Inflammation; Insulin resistance; Metabolic syndrome; Obesity

Indexed keywords

EID: 84896183046     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (105)

1. Cyrus T, Sung S, Zhao L, Funk CD, Tang S, Praticò D. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 2002; 106(10):1282-1287.
2. Das UN. Is metabolic syndrome X an inflammatory condition? Exp Biol Med (Maywood) 2002; 227(11):989-997.
3. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 2001; 38(3):581-587.
4. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003; 144(6):2195-2200.
5. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116(7):1793-1801.
6. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of Metabolic Syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004; 109:433-438.
7. Rojas R, Aguilar-Salinas CA, Jiménez-Corona A, Shamah-Levy T, Rauda J, Avila- Burgos L, Villalpando S, Ponce EL. Metabolic Salud Publica Mex 2010; 52:S11-8.
8. Olivares-Reyes JA, Plancarte AA, Castillo-Hernandez JR. Angiotensin II and the development of insulin Mol Cell Endocrinol 2008; 302:128-39.
9. Eriksson JW. Metabolic FEBS Lett 2007; 581:3734-3742.
10. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25(1):4-7.
11. Morley JE. The metabolic syndrome and aging. J Gerontol A Biol Sci Med Sci 2004; 59(2):139-42.
12. Kobayasi R, Akamine EH, Davel AP. Oxidative stress and inflammatory mediators contribute to endothelial dysfunction in high-fat diet induced obesity in mice. J Hypertens 2010; 28(10):2111-9.
13. Sriwijitkamol A, Coletta DK, Wajcberg E, Balbontin GB, Reyna SM, Barrientes J, Eagan PA, Jenkinson CP, Cersosimo E, DeFronzo RA, Sakamoto K, Musi N. Effect of acute exercise on AMPK signaling in skeletal muscle of subjects with Type 2 diabetes: a time-course and dose-response study. Diabetes 2007; 56:836-848.
14. Edwards KM, Ziegler MG, Mills PJ The potential anti-inflammatory benefits on improving physical fitness in hypertension. J Hypertens 2007; 25:1533-1542.
15. De Ciuceis C, Porteri E, Rizzoni D, Corbellini C, La Boria E, Boari GEM, Pilu A, Mittempergher F, Di Betta E, Casella C, Nascimbeni R, Rosei CA, Ruggeri G, Caimi L, Rosei EA. Effects of weight los son structural and functional alterations of subcutaneous small arteries in obese patients. Hypertension 2011; 58:29-36.
16. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs Nat New Biol 1971; 231:232-235.
17. Glasser SP, Cushman M, Prineas R, Kleindorfer D, Prince V, You Z, Howard VJ,Howard G. Does differential prophylactic aspirin use contribute to racial and geographic disparities in stroke and coronary heart disease (CHD)? Prev Med 2008; 47(2):161-166.
18. Hawkey CJ. COX-1 and COX-2 inhibitors. Best Pract Res Clin Gastroenterol 2001; 15(5):801-20.
19. Anfossi G, Russo I, Trovati M. Platelet dysfunction in central obesity. Nutr Metab Cardiovasc Dis 2009; 19(6):440-9.
20. Zhang L, Zheng J, Li HM, Meng YX. Inhibitory effects of cardiotonic pills on platelet function in dogs fed a high-fat diet. Blood Coagul Fibrinolysis 2006; 17(4):259-64.
21. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444:875-880.
22. Yang R, Barouch LA. Leptin signaling and obesity cardiovascular consequences. Circ Res 2007; 101:545-559.
23. Fortuño A, Bidegain J, Baltanás A, Moreno MU, Montero L, Landecho MF, Beloqui O, Díez J, Zalba G. Is leptin involved in phagocytic NADPH oxidase overactivity in obesity? Potential clinical implications. J of Hypert 2010; 28:1944-1950.
24. Perkins ND, Gilmore TD. Good cop, bad cop: the different faces of NF-?B. Cell Death and Differentiation 2006; 13:759-772.
25. Palomer X, Pérez A, Blanco-Vaca F. Adiponectin: a new link between obesity, insulin resistance and cardiovascular disease. Med Clin (Barc). 2005; 124(10):388-95.
26. Touyz RM. Intracellular mechanisms involved in vascular remodeling of resistance arteries in hypertension: role of angiotensin II. Exp physiol 2005; 90(4):449-455.
27. Hug C, Lodish HF. The role of the adipocyte hormone adiponectin in cardiovascular disease. Curr Opin Pharmacol 2005; 5(2):129-134.
28. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe, K. Adiponectin and adiponectin receptors in insulin resistance, diabetes and the metabolic syndrome. J Clin Invest 2006; 116:1784-1792.
29. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Adiponectin, an adipocyte-derived plasma protein, inhibits endotelial NF-kappa B signaling through a cAMP-dependent pathway. Circulation 2000; 102(11):1296-301.
30. Kobashi C, Urakaze M, Kishida M, Kibayashi E, Kobayashi H, Kihara S, Funahashi T, Takata M, Temaru R, Sato A, Yamazaki K, Nakamura N, Kobayashi M. Adiponectin inhibits endothelial synthesis of interleukin-8 Circ Res 2005; 97(12):1245-1252.
31. Butler J, Kalogeropoulos A, Georgiopoulou V, de Rekeneire N, Rodondi N, Smith AL, Hoffmann U, Kanaya A, Newman AB, Kritchevsky SB, Vasan RS, Wilson PW, Harris TB. Serum resistin concentrations and risk of new onset heart failure in older persons: The health, aging, and body composition (Health ABC) study. Arterioscler Thromb Vasc Biol 2009; 29:1144-1149.
32. Chen C, Jiang J, Lü JM, Chai H, Wang X, Lin PH, Yao Q. Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol 2010; 299:H193- H201.
33. Mu H, Ohashi R, Yan S, Chai H, Yang H, Lin P, Yao Q, Chen C. Adipokine resistin promotes in vitro angiogenesis of human endothelial cells Cardiovasc Res 2006; 70:146-157.
34. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005; 174:5789-5795.
35. de Souza Batista CM, Rong-Ze Y, Lee MJ, Glynn LM, Yu DZ, Pray J, Ndubuizu K, Patil S, Schwartz A, Kligman M, Fried SK, Gong DW, Shuldiner AR, Pollin TI, McLenithan JC. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007; 56:1655-1661.
36. Fajas L, Miard S, Briggs MR, Auwerx J. Selective cyclo-oxygenase-2 inhibitors impair adipocyte differentiation through inhibition of the clonal expansion phase. J Lipid Res 2003; 44(9):1652-9.
37. Fujita K, Nozaki Y, Wada K, Yoneda M, Endo H, Takahashi H, Iwasaki T, Inamori M, Abe Y, Kobayashi N, Kirikoshi H, Kubota K, Saito S, Nagashima Y, Nakajima A. Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. Gut. 2008;57(11):1583-91.
38. Nonogaki K, Fuller GM, Fuentes NL, Moser AH, Staprans I, Grunfeld C, Feingold KR. Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology 1995; 136(5):2143-2149.
39. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280(5):E745-751.
40. Mitrou P, Boutati E, Lambadiari V, Tsegka A, Raptis AE, Tountas N, Economopoulos T, Raptis SA, Dimitriadis G. Insulin resistance in hyperthyroidism: the role of IL6 and TNF. Eur J Endocrinol 2010; 162:121-126.
41. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res 2004; 95(8):764-72.
42. Fridman O, Fuchs AG, Porcile R, Morales AV, Gariglio LO. Paraxonasa: sus multiples funciones y regulación farmacológica. Arch Cardiol Mex 2011; 81(3):251-260.
43. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006; 444:847-853.
44. Kim F, Pham M, Luttrell I, Bannerman DD, Tupper J, Thaler J, Hawn TR, Raines EW, Schwartz MW. Toll-Like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ Res 2007; 100:1589-1596.
45. Böni-Schnetzler M, Boller S, Debray S, Bouzakri K, Meier DT, Prazak R, Kerr-Conte J, Pattou F, Ehses JA, Schuit FC, Donath MY. Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 2009; 150:5218-5229.
46. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, Van Pelt RE, Wang H, Eckel RH. The metabolic syndrome. Endocrine Reviews 2008; 29:777- 822.
47. Huacuja Álvarez F, Gómez Duque M, Ortiz Vargas JC, Soberanes Velázquez B, Arévalo Moreno V, Morales Villegas E, Sánchez-Reyes L, Fanghänel G. Efecto de las estatinas más allá del colesterol. Revista de Endocrinología y Nutrición 2006; 14 (2):73-88.
48. Meyer-Sabellek W, Brasch H. Atherosclerosis, inflammation, leukocyte function and the effect of statins. J Hypertens 2006; 24:2349-2351.
49. Zambon A, Gervois P, Pauletto P, Fruchart JC, Staels B. Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-?activators: clinical and experimental evidence. Arterioscler Thromb Vasc Biol 2006; 26:977-986.
50. Tegeder I, Pfeilschifter J, Grisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001; 15: 2057-2072.
51. Inoue M, Itoh H,Tanaka T, Chun TH, Doi K, Fukunaga Y, Sawada N, Yamshita J, Masatsugu K, Saito T, Sakaguchi S, Sone M, Yamahara Ki, Yurugi T, Nakao K. Oxidized LDL regulates vascular endothelial growth factor expression in human macrophages and endothelial cells through activation of peroxisome proliferatoractivated receptor-gamma. Arterioscler Thromb Vasc Biol 2001; 21(4):560-6
52. Athyros VG, Tziomalos K, Mikhailidis DP, Pagourelias ED, Kakafika AI, Skaperdas A, Hatzitolios A, Karagiannis A. Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia? Expert Opin Pharmacother 2007; 8(14):2267-77.
53. Park E, Wong V, Guan X, Oprescu AI, Giacca A. Salicylate prevents hepatic insulin resistance caused by short-term elevation of free fatty acids in vivo. J Endocrinol 2007; 195(2):323-31.
54. Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H, Quon MJ. Roles for insulin receptor PI3Kinase and Akt in insulin signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 2000; 101:1539-1545.
55. Muniyappa R, Iantorno M, Quon MJ. An integrated view of insulin resistance and endothelial dysfunction. Endocrinol Metab Clin N Am 2008; 37:685-711.
56. Iaccarino G, Ciccarelli M, Sorriento D, Cipolletta E, Cerullo V, Iovino GL, Paudice A, Elia A, Santulli G, Campanile A, Arcucci O, Pastore L. Akt participates in endothelial dysfunction in hypertension. Circulation 2004; 109:2587-2593.
57. Schwartz EA, Reaven PD. Molecular and signaling mechanisms of atherosclerosis in insulin resistance. Endocrinol Metab Clin N Am 2006;35:525-549.
58. Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS. A central role for JNK in obesity and insulin resistance. Nature 2002; 420(6913):333-336.
59. Mathews ST, Kim T. Fetuin-A a novel regulator of insulin action: role in insulin resistance En: Yao EB (Editor). Insulin resistance: new research. New York. Nova Science Publishers, Inc. 2009, p.99-116.
60. Chen HY, Chiu YL, Hsu SP, Pai MF, Lai CF, Peng YS, Kao TW, Hung KY, Tsai TJ, Wu KD. Association of serum fetuin A with truncal obesity and dyslipidemia in nondiabetic emodialysis patients. Eur J Endocrinol 2009; 160:777-783.
61. Ix JH, Sharma K. Mechanisms linking obesity, chronic kidney disease and fatty liver disease: The roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol 2010; 21:406-412.
62. Jager J, Grémeaux T, Cormont M, Le Marchand-Brustel Y, Tanti JF. Interleukin-1- beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology 2007; 148:241-251.
63. Sandler S, Bendtzen K, Eizirik D, Welsh M Interleukin-6 affects insulin secretion and glucose metabolism of rat pancreatic islets in vitro. Endocrinology 1990; 126:1288- 1294.
64. Fernández-Real JM, Ricart W, Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocrine Reviews 2003; 24:278-301.
65. Boden G, She P, Mozzoli M, Cheung P, Gumireddy K, Reddy P, Xiang X, Luo Z, Ruderman N. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear Factor-?B pathway in rat liver. Diabetes 2005; 54:3458-3465.
66. Kamide K, Rakugi H, Nagai M, Takiuchi S, Matsukawa N, Higaki J, Kawano Y, Ogihara T, Tuck ML. Insulin mediated regulation of the endothelial-renin-anigiotensin system and vascular cell growth. J Hyperten 2004; 22:121-127.
67. Lee DH, Lee JU, Kang DG, Paek YW, Chung DJ, and Chung, MY Increased vascular endothelin-1 gene expression with unaltered nitric oxide syntase levels in fructoseinduced hypertensive rats. Metabolism 2001; 50(1):74-78.
68. Nyby MD, Abedi K, Smutko V, Eslami P, Tuck ML. Vascular angiotensin type 1 receptor expression is associated with vascular dysfunction oxidative stress and inflammation in fructose-fed rats. Hypertens Res 2007; 30(5):451-457.
69. Rubio ME, Baños G, Díaz E, Guarner V. Effect of age on insulin-induced endothelin release and vasoreactivity in hypertriglyceridemic and hypertensive rats. Exp Gerontol 2006; 41(3):282-288.
70. Samaha FF, Szapary PO, Iqbal N, Williams MM, Bloedon LT, Kochar A, Wolfe ML, Rader DJ. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low High-Density Lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol 2006; 26:624-630.
71. Bashmakov YK and Petyaev IM. Old Drug Acquires New Target: Metformin and Sirt1. J Diabetes Metab 2011; 2:107e. doi:10.4172/2155-6156.1000107e
72. Zhang J, Wang J, Wu H, He Y, Zhu G, Cui X, Tang L. Design, synthesis and insulinsensitizing activity of indomethacin and diclofenac derivatives. Bioorg Med Chem Lett. 2009; 19(12):3324-7.
73. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang H, Abumrad N, Eaton JW, Tracey KJ. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000; 405:458-462.
74. Cho L, Tsunoda M, Sharma RP Effects of endotoxin and tumor necrosis factor-? on regional brain neurotransmitters in mice. Nat Toxins 1990; 7:187-195.
75. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension 2001; 38:399-403.
76. Woods M, Mitchell JA, Wood EG, Barker S, Walcot NR, Endothelin-1 is induced by cytokines in human vascular smooth muscle cells: evidence for intracellular endothelinconverting enzyme. Mol Pharmacol 1999; 55:902-909.
77. Wang W, Yen H, Chen CH, Soni R, Jasani N Barker S, Walcot NR, Rees GM, Warner TD. The endothelin-converting enzyme-1/endothelin-1 pathway plays a critical role in inflammation-associated premature delivery in a mouse model. Am J Pathol 2008; 173:1077-1084.
78. Wang W, Yen H, Chen CH, Jasani N, Soni R, Koscica K, Reznik SE. Prevention of inflammation-associated preterm birth by knockdown of the endothelin-1-matrix metalloproteinase-1 pathway. Mol Med 2010; 16(11-12):505-512.
79. Quilley J. Oxidative stress and inflammation in the endothelial dysfunction of obesity: a role for nuclear factor kappa B? J Hyperten 2010; 28:2010-2011.
80. Touyz RM, Yao G, Viel E, Amiri F, Schiffrin EL. Angiotensin II and endothelin-1 regulate MAP kinases through different redox-dependent mechanisms in human J Hypertens 2004; 22(6):1141-9.
81. Kobayashi T, Hayashi Y, Taguchi K, Matsumoto T, Kamata K. Angiotensin II enhances contractile responses via PI3-Kinase p110? pathway in aortas from diabetic rats with systemic hyperinsulinemia. Am J Heart Circ Physiol 2006; 291: H846-H853.
82. Csiszar, A., Wang, M., Lakatta, E. and Ungvari, Z. Inflammation and endothelial dysfunction during aging: role of NF-kappaB., J Appl Physiol 2008; 105:1333-1341.
83. Sanz-Rosa D, Oubiña MP, Cediel E, de Las Heras N, Vegazo O, Jiménez J, Lahera V, Cachofeiro V. Effect of AT1 receptor antagonism Am J Physiol Heart Circ Physiol 2005; 288(1):H111-5.
84. Nickenig G, Harrison DG. The AT1-type angiotensin receptor in oxidative stress and atherogenesis. Circulation 2002; 105:393-396.
85. Takata Y, Osawa H, Kurata M, Kurokawa M, Yamauchi J, Ochi M, Nishida W, Okura T, Higaki J, Makino H. Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes. Hypertension 2008; 51:534-539.
86. Gentile MT, Vecchione C, Marino G, Aretini A, Di Pardo A, Antenucci, G., Maffei, A., Cifelli, G., Iorio, L., Landolfi, A., Frati, G., and Lembo, G. Resistin impairs insulinevoked vasodilation. Diabetes 2008; 57:577-583.
87. Chen C, Jiang J, Lü JM, Chai H, Wang X. Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol 2010; 299:H193-H201.
88. Kim F, Tysseling KA, Rice J, Pham M, Haji L, Gallis BM, Baas AS, Paramsothy P, Giachelli CM, Corson MA, Raines EW. Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKK??Arterioscler Thromb Vasc Biol 2005; 25:989-994.
89. Wu R, Lamontagne D, de Champlain J Antioxidative properties of acetylsalicylic acid on vascular tissues from normotensive and spontaneously hypertensive rats. Circulation 2002; 105:387-392.
90. Deng S, Deng PY, Jiang JL, Ye F, Yu J, Yang TL, Deng HD, Li YJ. Aspirin protected against endothelial damage induced by LDL: role of endogenous NO synthase inhibitors in rats. Acta Pharmacol Sin 2004; 25(12):1633-1639.
91. Bulckaen H, Prévost G, Boulanger E, Robitaille G, Roquet V, Gaxatte C, Garçon G, Corman B, Gosset P, Shirali P, Creusy C, Puisieux F. Low-dose aspirin prevents agerelated endothelial dysfunction in a mause model of physiological aging Am J Physiol Heart Circ Physiol 2008; 294:H1562-H1570.
92. Raghavan RP, Laight DW, Shaw KM, Cummings MH. Aspirin and diabetes Br J Diabetes Vasc Dis 2006; 6:74-82.
93. Manabe S, Okura T, Watanabe S, Fukuoka T, Higaki J. Effects of angiotensin II J Cardiovasc Pharmacol 2005; 46(6):735-9.
94. Edwards KM, Ziegler MG, Mills PJ The potential anti-inflammatory benefits on improving physical fitness in hypertension. J Hypertens 2007; 25:1533-1542.
95. Kohlstedt K, Gershome C, Trouvain C, HofmannWK, Fichtlscherer S, Fleming I. Angiotensin-converting enzyme (ACE) inhibitors modulate cellular retinol-binding protein 1 and adiponectin expression in adipocytes via the ACE-dependent signaling cascade. Mol Pharmacol 2009; 75:685-692.
96. Harris RC. An update on cyclooxygenase-2 expression and metabolites in the kidney. Curr Opin Nephrol Hypertens 2008; 17(1):64-69.
97. Wilson, SL, Poulter NR. The effect of non-steroidal anti-inflammatory drugs and other commonly used non-narcotic analgesics on blood pressure level in adults. J Hypertension 2006; 24:1457-1469.
98. White WB. Cardiovascular effects of the cyclooxygenase inhibitors. Hypertension 2007; 49:408-418.
99. Alvarez-Nemegyei J, Rubio-Solís ENJ, Herrera-Correa GM. Efecto del tratamiento a corto plazo con antiinflamatorios no esteroideos en la presión arterial media. Un ensayo clínico aleatorizado. Reumatol Clin 2006; 2(1):10-14.
100. Rompe F, Artuc M, Hallberg A, Alterman M, Ströder K, Thöne-Reineke C, Reichenbach A, Schacherl J, Dahlöf B, Bader M, Alenina N, Schwaninger M, Zuberbier T, Funke-Kaiser H, Schmidt C, Schunck WH, Unger T, Steckelings UM. Direct Angiotensin II type 2 receptor stimulation acts anti-Inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor- ?B. Hypertension 2010; 55:924-931.
101. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008; 54(1):24-38.
102. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286(8):954-9.
103. Weir MR, Sperling RS, Reicin A, Gertz BJ. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J 2003; 146(4):591-604.
104. Konstam MA, Weir MR. Current perspective on the cardiovascular effects of coxibs. Cleve Clin J Med 2002; 69 Suppl 1:SI47-52.
105. Franco OH, Karnik K, Bonneux L. The future of metabolic syndrome and cardiovascular disease prevention: polyhype or polyhope? Tales from the polyera. Horm Metab Res 2007; 39(9):627-31.